The partnership with Walter Reed Army Institute of Research provides the French drugmaker access to a promising new vaccine that’s made from inactivated virus and has already shown positive results in mice.
Through the agreement, WRAIR will transfer virus vaccine technology to Sanofi Pasteur, the company’s vaccine division.
The U.S. National Institute of Allergy and Infectious Diseases will conduct Phase I trials during the technology transfer, with Sanofi then taking over to lead clinical and regulatory development.
The vaccine — currently one of the most advanced in the development process — could be ready for human testing as soon as October.
More articles on vaccines:
GSK’s malaria vaccine shows diminished efficacy after 7 years
Drugmakers target vaccines for a new market: pregnant women
German researchers test ‘universal cancer vaccine’
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.